Literature DB >> 2584707

Differential expression of the IL-2 receptor subunits, p55 and p75 on various populations of primary peripheral blood mononuclear cells.

Y Ohashi1, T Takeshita, K Nagata, S Mori, K Sugamura.   

Abstract

Unstimulated PBL were examined for expression of IL-2R subunits, IL-2Rp55 and IL-2Rp75, by two-color flow cytometric analyses using mAb. NKH-1+ non-T non-B cells expressed IL-2Rp75 but not IL-2Rp55, and the IL-2Rp75 sites on purified NKH-1+ cells were determined to be 1630 sites/cell by binding of 125I-labeled TU27 mAb specific for IL-2Rp75. In the CD4+ T cell population, IL-2Rp55+ cells were significantly detected, but little or marginally of the IL-2Rp75+ cells. However, IL-2Rp75+ cells were significantly detected, but little of the IL-2Rp55+ cells in the CD8+ T cell population. The IL-2Rp75 sites on CD8+ T cells were estimated at approximate 180-410 sites/cell. In the CD4+ T cells, expression of IL-2Rp75 as well as IL-2Rp55 was induced by stimulation with PHA. IL-2Rp75+ cells, but not IL-2Rp55+ cells, were also detected in the CD14+ monocyte population. In the CD20+ B cell population, a small number of IL-2Rp55+ cells was detected, but little of the IL-2Rp75+ cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2584707

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  46 in total

1.  Evidence for the presence of activated CD4 T cells with naive phenotype in the peripheral blood of patients with rheumatoid arthritis.

Authors:  D Maurer; T Felzmann; W Holter; P Petera; J Smolen; W Knapp
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

Review 2.  Immunotherapy through the IL-2 receptor.

Authors:  H A Verheul; M Verveld; E S Bos
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

3.  Levels of expression of complement regulatory proteins CD46, CD55 and CD59 on resting and activated human peripheral blood leucocytes.

Authors:  Stephen E Christmas; Claudia T de la Mata Espinosa; Deborah Halliday; Cheryl A Buxton; Joanne A Cummerson; Peter M Johnson
Journal:  Immunology       Date:  2006-09-26       Impact factor: 7.397

4.  Expression of activation antigens CD69, HLA-DR, interleukin-2 receptor-alpha (IL-2R alpha) and IL-2R beta on T cells of human decidua at an early stage of pregnancy.

Authors:  S Saito; K Nishikawa; T Morii; N Narita; M Enomoto; M Ichijo
Journal:  Immunology       Date:  1992-04       Impact factor: 7.397

5.  Tumour-infiltrating lymphocytes in primary melanoma: functional consequences of differential IL-2 receptor expression.

Authors:  J C Becker; A Schwinn; R Dummer; G Burg; E B Bröcker
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

6.  Lymphocytic choriomeningitis virus-induced immunodepression: inherent defect of B and T lymphocytes.

Authors:  M F Saron; B Shidani; M A Nahori; J C Guillon; P Truffa-Bachi
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

Review 7.  Exercise and the immune system. Natural killer cells, interleukins and related responses.

Authors:  R J Shephard; S Rhind; P N Shek
Journal:  Sports Med       Date:  1994-11       Impact factor: 11.136

8.  Coexpression of Fc gamma receptor IIIA and interleukin-2 receptor beta chain by a subset of human CD3+/CD8+/CD11b+ lymphocytes.

Authors:  S Zupo; L Azzoni; R Massara; A D'Amato; B Perussia; M Ferrarini
Journal:  J Clin Immunol       Date:  1993-05       Impact factor: 8.317

9.  Interleukin 2 modulates ion secretion and cell proliferation in cultured human small intestinal enterocytes.

Authors:  E V O'Loughlin; G P Pang; R Noltorp; C Koina; R Batey; R Clancy
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

10.  Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.

Authors:  J W Gratama; R J Bruin; C H Lamers; R Oosterom; E Braakman; G Stoter; R L Bolhuis
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.